China Medical GatewayLoading your healthcare gateway…

Hematopoietic Stem Cell Transplantation in China

Overview

Hematopoietic stem-cell transplantation replaces a patient’s blood-forming system after high-dose therapy, curing leukemias, lymphomas, inherited blood disorders and selected immune and metabolic diseases.

Chinese transplant centers pioneered haplotype-identical (half-matched family donor) transplantation — now standard worldwide — meaning virtually every patient has a potential donor.

Symptoms & Signs

Transplant is a treatment, not a symptom-driven procedure — indications include leukemia in remission with high relapse risk

Relapsed or refractory lymphoma and myeloma after salvage therapy

Severe aplastic anemia with failing marrow

Inherited disorders: thalassemia major, sickle-cell disease, immunodeficiency syndromes

Prior failure of conventional chemotherapy or targeted therapy

Molecular markers — such as persistent minimal residual disease — indicating high risk without transplant

Diagnosis

Full re-staging of the underlying disease before conditioning

HLA typing of patient and potential family donors; unrelated donor registry searches

Donor selection incorporating age, health and matching quality

Comprehensive organ-function assessment: heart, lung, liver, kidney

Infection screening including hepatitis, CMV and respiratory viruses

Fertility-preservation counseling before conditioning begins

Treatment Options

Autologous transplant: the patient’s own stem cells rescue marrow after high-dose therapy

Allogeneic transplant from matched sibling, unrelated or haplotype donors

Reduced-intensity conditioning for older or less-fit patients

Graft-versus-host disease prevention and treatment protocols

Post-transplant immune monitoring and infection prophylaxis

Relapse surveillance with molecular minimal-residual-disease testing

Advanced Technologies & Novel Drug

Haplotype-identical transplant platforms originated at Chinese centers

GMP cell-processing laboratories for graft engineering and manipulation

JAK-inhibitor and post-transplant cyclophosphamide GVHD prophylaxis

Molecular minimal-residual-disease monitoring guiding intervention

Novel post-transplant maintenance agents for relapse prevention

Hospital & Specialist

Return to Home